Vasudevan Anil, Lodha Rakesh, Kabra S K
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Indian J Pediatr. 2004 Aug;71(8):743-50. doi: 10.1007/BF02730667.
Acute lung injury and acute respiratory distress syndrome are an important challenge for pediatric intensive care units. These disorders are characterized by a significant inflammatory response to a local (pulmonary) or remote (systemic) insult resulting in injury to alveolar epithelial and endothelial barriers of the lung, acute inflammation and protein rich pulmonary edema. The reported rates in children vary from 8.5 to 16 cases / 1000 pediatric intensive care unit (PICU) admissions. The pathological features of ARDS are described as passing through three overlapping phases - an inflammatory or exudative phase (0-7 days), a proliferative phase (7-21 days) and lastly a fibrotic phase (from day 10). The treatment of ARDS rests on good supportive care and control of initiating cause. The goal of ventilating patients with ALI/ARDS should be to maintain adequate gas exchange with minimal ventilator induced lung injury. This can be achieved by use of optimum PEEP, low tidal volume and appropriate FiO2. High frequency ventilation can improve oxygenation but does affect the outcomes. Prone positioning is a useful strategy to improve oxygenation. Pharmacological strategies have not made any significant impact on the outcomes. Preliminary data suggests some role for use of corticosteroids in non-resolving ARDS. The mortality rates have declined over the last decade chiefly due to the advances in supporting critically ill patients.
急性肺损伤和急性呼吸窘迫综合征是儿科重症监护病房面临的一项重大挑战。这些病症的特点是对局部(肺部)或远程(全身性)损伤产生显著的炎症反应,导致肺的肺泡上皮和内皮屏障受损、急性炎症和富含蛋白质的肺水肿。据报道,儿童发病率为每1000例儿科重症监护病房(PICU)入院病例中有8.5至16例。急性呼吸窘迫综合征的病理特征被描述为经历三个重叠阶段——炎症或渗出期(0 - 7天)、增殖期(7 - 21天),最后是纤维化期(从第10天开始)。急性呼吸窘迫综合征的治疗依赖于良好的支持性护理和对引发病因的控制。对急性肺损伤/急性呼吸窘迫综合征患者进行通气的目标应该是以最小的呼吸机诱发肺损伤维持充分的气体交换。这可以通过使用最佳呼气末正压、低潮气量和适当的吸氧浓度来实现。高频通气可以改善氧合,但对治疗结果有影响。俯卧位是改善氧合的一种有效策略。药物治疗策略对治疗结果没有产生任何显著影响。初步数据表明,皮质类固醇在难治性急性呼吸窘迫综合征中可能有一定作用。在过去十年中,死亡率有所下降,这主要归功于危重症患者支持治疗方面的进展。